S. Oro

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study

Sylvie Bastuji‐Garin, P. Joly, Pauline Lemordant et al. · Journal of Investigative Dermatology · 2010 · 295 citations · Full text

Geriatrics, Bullous Pemphigoid, Public Health +3

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

Natacha Colliou, D Picard, Frédérique Caillot et al. · Science Translational Medicine · 2013 · 238 citations

Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients

C. Hotz, L. Valeyrie‐Allanore, Cynthia Haddad et al. · British Journal of Dermatology · 2013 · 151 citations

Prognostic Factors of Paraneoplastic Pemphigus

Sandy Léger, D Picard, S. Oro et al. · Archives of Dermatology · 2012 · 150 citations